BR0015781A - Pharmaceutical composition for treatment of diseases associated with decreased bone mass - Google Patents
Pharmaceutical composition for treatment of diseases associated with decreased bone massInfo
- Publication number
- BR0015781A BR0015781A BR0015781-3A BR0015781A BR0015781A BR 0015781 A BR0015781 A BR 0015781A BR 0015781 A BR0015781 A BR 0015781A BR 0015781 A BR0015781 A BR 0015781A
- Authority
- BR
- Brazil
- Prior art keywords
- diseases associated
- bone mass
- pharmaceutical composition
- treatment
- decreased bone
- Prior art date
Links
Abstract
"COMPOSIçãO FARMACêUTICA PARA TRATAMENTO DE DOENçAS ASSOCIADAS à DIMINUIçãO DE MASSA óSSEA". Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea compreendendo um agonista EP, como um ingrediente ativo. Um agonista EP, que inclui um composto possuindo esqueleto de prostaglandina como representativo, possui ação de promover a formação óssea, assim ele é útil para tratamento e/ou prevenção de doenças associadas à diminuição de massa óssea."PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH THE DECREASE IN BONE MASS". Pharmaceutical composition for treating diseases associated with decreased bone mass comprising an EP agonist, as an active ingredient. An EP agonist, which includes a compound having a prostaglandin skeleton as representative, has the action of promoting bone formation, so it is useful for treating and / or preventing diseases associated with decreased bone mass.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33349099 | 1999-11-24 | ||
| JP2000056534 | 2000-03-01 | ||
| PCT/JP2000/008235 WO2001037877A1 (en) | 1999-11-24 | 2000-11-22 | Remedies for diseases in association with decrease in bone mass |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0015781A true BR0015781A (en) | 2002-12-31 |
Family
ID=26574530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0015781-3A BR0015781A (en) | 1999-11-24 | 2000-11-22 | Pharmaceutical composition for treatment of diseases associated with decreased bone mass |
Country Status (2)
| Country | Link |
|---|---|
| BR (1) | BR0015781A (en) |
| RU (1) | RU2259830C2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200808123B (en) | 2006-03-24 | 2010-03-31 | Childrens Medical Center | Method to modulate hematopoietic stem cell growth |
| WO2008070310A2 (en) | 2006-10-20 | 2008-06-12 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| US9056085B2 (en) | 2009-02-03 | 2015-06-16 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| WO2010091052A2 (en) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| RU2452483C1 (en) * | 2010-12-23 | 2012-06-10 | Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) | Method for prevention of osteoporosis accompanying preoperative chemotherapy in patients suffering stage iii non-small-cell lung cancer |
| CA2857640C (en) | 2011-12-02 | 2021-11-16 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| ES2682255T3 (en) | 2011-12-02 | 2018-09-19 | Fate Therapeutics, Inc. | Improved methods of ischemia treatment |
| EP2968416A4 (en) | 2013-03-15 | 2016-08-17 | Fate Therapeutics Inc | Cell potency assay for therapeutic potential |
-
2000
- 2000-11-22 BR BR0015781-3A patent/BR0015781A/en not_active IP Right Cessation
- 2000-11-22 RU RU2002113565/15A patent/RU2259830C2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2002113565A (en) | 2004-01-10 |
| RU2259830C2 (en) | 2005-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120313T1 (en) | MEDICINAL COMPOSITION FOR LEATHER USE TO TREAT PREVENTION WHICH INCLUDES Vitamin D And Corticosteroids | |
| BR0317747A (en) | Method of concomitant therapeutic treatment of an individual, pharmaceutical composition, kit, use of a first agent and a second agent, and methods of preventing or treating amyloid-b-related disease, alzheimer's disease and mild cognitive impairment | |
| BR9711805A (en) | Compounds and methods for providing pharmacologically active preparations and use | |
| EP1232757A4 (en) | Remedies for diseases in association with decrease in bone mass | |
| BR0110420A (en) | Muscarinic Agonists | |
| BR0213358A (en) | Flibanserin use | |
| BRPI0007487B8 (en) | diphenyl-ureas substituted with w-carboxy-aryls as raf kinase inhibitors | |
| BRPI0108977B8 (en) | azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof | |
| MY176938A (en) | 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d] pyrimidin-2-one compounds and prodrugs thereof | |
| DE60031396D1 (en) | PREPARATION FOR THE TREATMENT OF A NEUROLOGICAL DISEASE | |
| BR9709915A (en) | Compound pharmaceutical composition use of the compound and processes for the treatment or prevention of physiological disorders associated with an excess of tachykinins and for the preparation of the compound | |
| BRPI0412526A (en) | compound, use of a compound, pharmaceutical composition, pharmaceutical aerosol formulation, and method for treating a human or animal patient with an anti-inflammatory and / or allergic condition | |
| GT199700009AA (en) | COMBINED THERAPY FOR OSTEOPOROSIS | |
| UY26130A1 (en) | COMPOUNDS TO TREAT OBESITY | |
| BR0107667A (en) | Crystal linezolid compound which is pharmaceutically useful as an antibacterial agent and method of preparing it | |
| BR9908510A (en) | Use of a compound, compound, process for preparing a compound, pharmaceutical composition, and process for treating a patient suffering from, or at risk for, a mycobacterial disease | |
| FI951856A0 (en) | Pharmaceutical composition for the treatment of osteoporosis | |
| BR9916575A (en) | Pharmaceutical composition of controlled release with tilidine mesylate as active substance | |
| BR0211932A (en) | Methods and compositions for oral administration of parathyroid hormone, pth | |
| AR001790A1 (en) | Transdermal patch formulations for treating modeled muscarinic receptor conditions | |
| AR023687A1 (en) | A COMPOSITION FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS AND THE USE OF A GLUTAMATE ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS | |
| BR0015781A (en) | Pharmaceutical composition for treatment of diseases associated with decreased bone mass | |
| BR0010983A (en) | Preparations for the application of anti-inflammatory agents | |
| ES2177024T3 (en) | EMPLOYMENT OF THE FANQUINOMA FOR THE TREATMENT OF ALZHEIMER'S DISEASE. | |
| DE59914183D1 (en) | DISPOSABLE DEVICE FOR A COMPOSITION OF A PHARMACEUTICALLY ACTIVE SUBSTANCE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A, 10A E 11A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2142 DE 24/01/2012. |